Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2006 3
2007 2
2011 1
2014 1
2015 2
2016 1
2017 2
2018 2
2019 3
2020 5
2021 5
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Drilon A, et al. Among authors: cerea g. Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9. Cancer Discov. 2017. PMID: 28183697 Free PMC article. Clinical Trial.
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A, Pizzutilo EG, Marrapese G, Tosi F, Cerea G, Siena S. Sartore-Bianchi A, et al. Among authors: cerea g. Expert Rev Anticancer Ther. 2020 May;20(5):333-341. doi: 10.1080/14737140.2020.1747439. Epub 2020 Apr 8. Expert Rev Anticancer Ther. 2020. PMID: 32223357 Free article. Review.
What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review.
Agostara AG, Roazzi L, Villa F, Romano' R, Piscazzi D, Martinelli F, Ciarlo G, Oresti S, Travaglini F, Marando A, Sartore-Bianchi A, Giannetta L, Cerea G, Siena S, Pizzutilo EG, Signorelli D. Agostara AG, et al. Among authors: cerea g. Expert Rev Respir Med. 2023 Jul-Dec;17(9):787-803. doi: 10.1080/17476348.2023.2268509. Epub 2023 Oct 27. Expert Rev Respir Med. 2023. PMID: 37817448 Review.
Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer.
Sartore-Bianchi A, Cerea G, Schiavetto I, Giannetta L, Ricotta R, Maugeri MR, Moroni M, Marrapese G, Siena S. Sartore-Bianchi A, et al. Among authors: cerea g. Ann Oncol. 2006 Mar;17 Suppl 2:ii49-51. doi: 10.1093/annonc/mdj922. Ann Oncol. 2006. PMID: 16608982 Free article. Review. No abstract available.
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
Metro G, Signorelli D, Pizzutilo EG, Giannetta L, Cerea G, Garaffa M, Friedlaender A, Addeo A, Mandarano M, Bellezza G, Roila F. Metro G, et al. Among authors: cerea g. Hum Vaccin Immunother. 2021 Sep 2;17(9):2972-2980. doi: 10.1080/21645515.2021.1917933. Epub 2021 May 18. Hum Vaccin Immunother. 2021. PMID: 34003722 Free PMC article.
Biphenotypic lung carcinoma with coexpression of TTF-1 and ΔNP63/P40 within most of the same individual cells: a further case confirming poor prognosis and a review of literature.
Marando A, Zagni M, Negrelli M, Valtorta E, Lauricella C, Motta V, Veronese S, Cerea G, Giannetta LG, Ciarlo G, Signorelli D, Pizzutilo EG, Bonoldi E, Pelosi G. Marando A, et al. Among authors: cerea g. Pathologica. 2024 Feb;116(1):13-21. doi: 10.32074/1591-951X-957. Pathologica. 2024. PMID: 38482671 Free PMC article. Review.
36 results